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Abstract
Background: Because of the increasing life expectancy in our society, aging-related neurodegenerative disorders
are one of the main issues in global health. Most of these diseases are characterized by the deposition of misfolded
proteins and a progressive cognitive decline. Among these diseases, Alzheimer’s disease (AD) and dementia with
Lewy bodies (DLB) are the most common types of degenerative dementia. Although both show specific features,
an important neuropathological and clinical overlap between them hampers their correct diagnosis. In this work,
we identified molecular biomarkers aiming to improve the misdiagnosis between both diseases.
Methods: Plasma extracellular vesicles (EVs) -from DLB, AD and healthy controls- were isolated using size-exclusion
chromatography (SEC) and characterized by flow cytometry, Nanoparticle Tracking Analysis (NTA) and cryo-electron
microscopy. Next Generation Sequencing (NGS) and related bibliographic search was performed and a selected
group of EV-associated microRNAs (miRNAs) was analysed by qPCR.
Results: Results uncovered two miRNAs (hsa-miR-451a and hsa-miR-21-5p) significantly down-regulated in AD
samples respect to DLB patients, and a set of four miRNAs (hsa-miR-23a-3p, hsa-miR-126-3p, hsa-let-7i-5p, and
hsa-miR-151a-3p) significantly decreased in AD respect to controls. The two miRNAs showing decreased
expression in AD in comparison to DLB provided area under the curve (AUC) values of 0.9 in ROC curve
analysis, thus suggesting their possible use as biomarkers to discriminate between both diseases. Target gene
analysis of these miRNAs using prediction online tools showed accumulation of phosphorylation enzymes,
presence of proteasome-related proteins and genes involved in cell death among others.
Conclusion: Our data suggest that plasma-EV associated miRNAs may reflect a differential profile for a given
dementia-related disorder which, once validated in larger cohorts of patients, could help to improve the
differential diagnosis of DLB versus AD.
Keywords: Neurodegenerative disorders, Biomarker, Exosomes, Next generation sequencing, Extracellular
vesicles
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Background
Neurodegenerative disorders with largest economic burden
in our society include dementia syndromes such as Alzhei-
mer’s disease (AD), frontotemporal dementia, dementia
with Lewy bodies (DLB), and movement disorders namely
Parkinson’s disease (PD), in which about 50% of patients
may develop dementia 15 years after PD onset [1–3].
Clinically, along the course of the three diseases, a progres-
sive cognitive decline affecting the normal and social
functions of the patients is observed [4]. Moreover, neuro-
pathologically, a common neurodegeneration-related fea-
ture is the deposition of misfolded proteins. While in DLB
and PD α-synuclein accumulations, named Lewy bodies are
found [5], in AD –and also in about half of all DLB cases-
ß-amyloid senile plaques and hyperphosphorylated tau are
accumulated in the brain [6, 7]. Correspondingly, DLB
shows an important neuropathological and therefore clin-
ical overlap with both, PD and AD, hampering its correct
identification. Currently, a high proportion of DLB cases
are missed or misdiagnosed as AD, resulting in an incorrect
treatment of the patient, which leads to the development of
adverse reactions in 50% of these treated patients [7].
Over the past decade, the role of extracellular
vesicles (EVs) in the development and functioning of
the central nervous system has been deeply explored
[8–10]. EVs, such as exosomes (EXs) and microvesi-
cles (MVs), seem to be important effectors in the
development of cognitive and neurodegenerative
disorders. They have been shown to mediate the
transport of prions and misfolded pro-aggregating
proteins from cell to cell [11–14]. Because EVs are
produced by each individual cell and provide a pro-
tected environment to shuttle not only proteins but
also microRNAs (miRNAs) to the intercellular space
and to different body fluids, the study of their con-
tent has emerged as an area of interest in the bio-
marker field, also in neurodegenerative disorders
[15–18]. To date, several EV-associated miRNAs
have been identified as altered and related to neuro-
degenerative disorders [19–21]. Many of these stud-
ied EVs were obtained from cerebrospinal fluid
(CSF) samples. However, due to several issues on
CSF-collection (difficulty, invasiveness, morbidity,
risk), alternative sources such as plasma-derived EVs
have been lately reported [22, 23].
In this study, we analysed the miRNA profile associated
to plasma-derived EVs from DLB, AD and healthy controls.
We further investigated whether differences in the plasma-
EV-miRNA content could be of help to better characterize
neurodegenerative disorders, specifically DLB and AD. Our
data suggest that some plasma-EV associated miRNAs are
differentially found in DLB and AD patients, and thus could
help to improve the differential diagnosis of these overlap-
ping neurodegenerative disorders.
Materials and methods
Blood collection and sample processing
The Clinical Research Ethics Committee of our institu-
tion approved the following protocol and from each sub-
ject, written informed consent was obtained according
to the Declaration of Helsinki Principles [24]. DLB pa-
tients (n = 18; age range 62–84 years; mean 72.5 years;
male: female ratio 1:1.75) were recruited by neurologists
specialized in Lewy body disorders at the Dementia Unit,
Department of Neurology from the University Hospital
Bellvitge, (L’Hospitalet de Llobregat, Barcelona). Diagnosis
of DLB patients was established according to the 2005
DLB Consortium Criteria [25], and the age at onset was
defined as the age when parkinsonism or memory loss
was first reported by patients’ relatives. A group of age-
and gender-matched healthy individuals (n = 15; age-range
61–85; mean 70.5 years; male: female 1:2) from the same
hospital were also recruited. Finally, a group of AD pa-
tients (n = 10; age range 62–80; mean 71; male: female ra-
tio 1:1.5) was enrolled by the Neurology Department of
the University Hospital Germans Trias i Pujol. AD diagno-
sis was assessed following the 2011 revised criteria from
the National Institute on Aging and the Alzheimer’s
Association [26]. These patients presented a Global
Deterioration Scale of 4.3 ± 1.2 degrees. Clinical data of all
patients and healthy controls enrolled in this study are
shown in Table 1.
Blood samples from all participants were obtained
following ISEV- International Society for Extracellular
Vesicles- guidelines [27] and applying the same col-
lection protocol in both hospitals. In short, 15 mL of
peripheral blood were collected by venous puncture
using a 21-gauge needle coupled to a butterfly device
and using sodium citrate pre-treated tubes (BD Vacu-
tainer, New Jersey, USA) as described previously [28].
After discarding the first 2–3 ml, blood was collected
and mixed with the anticoagulant by gently inverting
tubes gently. Samples were processed within the first
2 h after collection. Plasma was clarified of platelets
and cells by consecutive centrifugation steps at 500 x
g for 10 min, 2500 x g for 15 min and a last step at
13,000 x g for 10 min. Plasma samples were frozen in
a freezing container with freezing rate of - 1 °C/min
and kept at − 80 °C until EV purification. Samples did
not suffer from more than 2 freeze-thaw cycles.
EV isolation by size exclusion chromatography (SEC)
Size Exclusion Chromatography (SEC) was used for isolat-
ing plasma-EVs as previously described [28]. Briefly, Seph-
arose-CL2B (Sigma Aldrich, St Louis, MO, USA) was
stacked in a Puriflash column Dry Load Empty 12 g (20/pk)
from Interchim (France)-Cromlab, S.L. (Barcelona, Spain).
Once the column was completely stacked, two mL of
plasma (previously thawed on ice) were loaded onto the
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Table 1 Data of patients and control individuals included in the study
Sample Clinical Diagnosis DatScan Gender Age (blood coll)a Age at onset MMSEb APOE
Ex1 DLB abnormal F 85 83 20 33
Ex2 DLB abnormal M 79 73 24 23
Ex3 DLB positive F 82 78 15 34
Ex4 DLB positive F 73 68 16 33
Ex5 DLB noc F 90 84 5 34
Ex6 DLB positive F 80 64 10 33
Ex7 DLB positive F 86 79 28 33
Ex8 DLB no F 79 74 19 34
Ex9 DLB positive M 74 67 6 33
Ex10 DLB positive F 79 74 12 33
Ex11 DLB positive M 65 59 5 33
Ex12 DLB positive M 77 67 24 33
Ex13 DLB positive F 83 80 16 33
Ex14 DLB positive M 70 62 12 33
Ex15 DLB positive F 77 73 18 34
Ex16 DLB positive M 63 59 15 33
Ex17 DLB positive F 64 62 11 nad
Ex18 DLB normal M 73 73 22 34
Ex19 AD – F 75 74 18 34
Ex20 AD – M 75 75 22 23
Ex21 AD – F 70 70 23 33
Ex22 AD – F 80 80 20 33
Ex23 AD – F 70 63 12 33
Ex24 AD – M 62 60 16 34
Ex25 AD – M 72 65 15 34
Ex26 AD – F 74 70 22 34
Ex27 AD – M 64 na 18 34
Ex28 AD – F 68 na 20 34
C-Ex1 CTRL – F 71 – 28 33
C-Ex2 CTRL – F 67 – 29 33
C-Ex3 CTRL – F 66 – 27 33
C-Ex4 CTRL – F 75 – 28 34
C-Ex5 CTRL – F 74 – 26 33
C-Ex6 CTRL – M 69 – 30 33
C-Ex7 CTRL – M 72 – 27 23
C-Ex8 CTRL – F 69 – 28 33
C-Ex9 CTRL – F 67 – 26 34
C-Ex10 CTRL – M 67 – 28 23
C-Ex11 CTRL – F 72 – 27 33
C-Ex12 CTRL – F 69 – 29 33
C-Ex13 CTRL – F 61 – 28 33
C-Ex14 CTRL – M 73 – 27 33
C-Ex15 CTRL – M 85 – 26 33
aage at blood collection; bMMSE: The Mini-Mental State Examination; cno DaTSCAN evaluation available; dnot available
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column and eluted with filtered PBS. A total of 20 fractions
(0.5mL each) were immediately collected.
EV characterization
EV fractions were characterized for their protein con-
centration, presence of specific EV-markers, size and
morphology.
As published before, protein concentration for each SEC
collected fraction was measured by absorbance at 280 nm
in a Thermo Scientific Nanodrop® ND-100 (Thermo Fisher
Scientific, Waltham, MA). Also, SEC-fractions were ana-
lysed for the presence of CD9, CD81, CD63 and CD5L as
specific EV-markers by bead-based flow cytometry assay
[28, 29]. Briefly, 50 μL of each fraction were incubated with
0.5 μL aldehyde/sulphate-latex beads-4 μm (Invitrogen,
Carlsbad, CA) for 15min at room temperature, re-sus-
pended in coupling buffer and incubated overnight. After
two washing steps with the same buffer, EV-coated beads
were incubated with anti-CD9 (Clone VJ1/20), anti-CD63
(Clone TEA 3/18), anti-CD5L (ab45408 from Abcam) and
anti-CD81 (clone 5A6, from Santa Cruz Biotech) or poly-
clonal IgG isotype (Abcam, Cambridge, UK) for 30min at
4 °C. After a washing step, samples were subjected to 30
min incubation at 4 °C with a FITC-conjugated secondary
goat anti-mouse antibody (Southern Biotech, Birmingham,
AL) for CD9, CD81 and CD63, and secondary Ab anti-
rabbit AlexaFLuor 488 (Invitrogen, Carlsbad, CA) for
CD5L. Two final washing steps were performed before ana-
lysing the samples by flow cytometry in a FacsVerse cyt-
ometer (BD Biosciences, New Jersey, USA). Mean
fluorescence intensity (MFI) values were plotted (Flow Jo
software, Tree Star, Ashland, OR) and tetraspanin-positive
fractions with the highest MFI (fractions 10–12 from our
SEC column) were considered as EV-containing fractions
and pooled for the forthcoming analysis.
Aiming to check EV morphology and size, EV-
enriched pools were also subjected to cryo-electron mi-
croscopy (cryo-EM) and to Nanoparticle Tracking Ana-
lysis (NTA) (n = 6), as reported earlier [28].
Isolation of microRNA
A volume of 750 μL of pooled EVs from each sample
was lyophilized at − 23 °C /overnight and used for
miRNA extraction using the miRCURYTM RNA Isola-
tion Kit-biofluids (Exiqon Vedbaek, Denmark) at room
temperature as described by the manufacturer. Briefly,
lyses solution and protein precipitation solution were
added to each sample. After incubation at room
temperature for 1 min, samples were centrifuged at 11,
000 x g for 3 min. Isopropanol was added to the super-
natants and the mix was transferred to the provided col-
umns. After a first centrifugation at 11,000 x g for 30 s,
several washing steps at the same centrifugation speed
with 1BF and 2BF solutions were applied. The column
was subjected to a last 2 min centrifugation to com-
pletely dry the membrane. MiRNA elution was per-
formed by adding 100 μL of RNase-free H2O directly
onto the membrane and centrifuging it for 1 min at 11,
000 x g. The obtained material was kept at − 80 °C until
further analysis.
In samples utilized for RT-qPCR validation experi-
ments, 2 artificial RNAs (UniSp4 and UniSp5 from the
RNA spike-in kit, Exiqon, Vedbaek, Denmark) were
spiked into the lysis buffer before miRNA purification,
according to the manufacturer’s protocol enabling the
assessment of miRNA purification and amplification
efficiency.
MicroRNA discovery by next generation sequencing (NGS)
and raw data analysis
The total volume of the obtained miRNAs from 7 DLB and
7 control samples was precipitated overnight at − 20 °C
with 1 μL of glycogen (20 μg/ μL), 10% 3M AcNa (ph 4.8)
and 2 volumes of absolute ETOH. miRNAs were re-sus-
pended in RNase free H2O and heated at 65 °C for 2–3
min. Quality control and size distribution of the purified
small RNA was assessed by Bioanalyzer 2100, (Agilent
Technologies, Santa Clara, USA).
The whole precipitated volume of each sample (10 μL)
was used for library preparation by NEBNext Multiplex
Small RNA Sample Preparation Set for Illumina (New
England Biolabs, Massachusetts, USA) following kit in-
structions. Individual libraries were subjected to the
quality analysis using a D1000 ScreenTape (TapeStation,
Agilent Technologies), quantified by fluorimetry and
pooled. Clustering and sequencing were done in an Illu-
mina Sequencer (MiSeq, Illumina, San Diego, USA) at 1
x 50c single read mode and 200,000 reads were obtained
for each sample. Obtained FastQ raw data were analysed
as follow: (1) Trimmomatic was used to remove the
adapter sequences from the reads [30]; (2) Reads were
mapped to the human genome using Bowtie2 algorithm
and individual miRNAs were identified [31]; (3) For each
sample, the number of reads mapped to a particular
miRNA sequence was counted; and (4) the total count
of reads was normalized applying the weighted trimmed
means of M-values (TMM) [32]. Before differential ex-
pression analysis, Lilliefors’ composite goodness-of-fit
test, Jarque-Bera hypothesis test and Shapiro-Wilk test
were applied to check the normality of our samples.
For NGS expression analysis the following criteria
were followed: at least minimum of 5 reads per sample
when present to considered a miRNA as present; present
in all patient samples (minimum of 5 reads) and absent
(less than 5 reads) in more than half of the control co-
hort; present in all control samples and absent in more
than half of the patients for presence/absence consider-
ation; present in most samples from both cohorts but
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differentially expressed between both groups. Differential
expression analysis for DLB versus control cohorts was
performed by Wilconson-rank sum test (p-value < 0.05)
[33] and validated by the Leave-One-Out (LOO) cross-
validation methodology.
Bibliographic search and miRNA selection
Literature search based on PubMed and The Nervous
System Disease NcRNAome Atlas (NSDNA) [34] data-
bases was performed aiming to identify miRNAs already
described as deregulated in dementia and neurodegener-
ative disorders. We then combined this bibliographic in-
formation with our data from NGS results in plasma-EV
from DLB and healthy control samples. Thus, a group of
15 highly represented miRNAs (all of them producing
more than 5000 reads in the NGS assay and belonging
to the top most abundant miRNAs identified by NGS)
were further considered for expression studies to com-
pare AD and DLB by qPCR.
Reverse transcription and qPCR analysis
MiRCURY LNATM Universal cDNA synthesis Kit II
and miRNA PCR system Pick & Mix (Exiqon, Ved-
baek, Denmark) were used for cDNA synthesis and
qPCR validation analysis of the selected miRNAs
according to the manufacturer’s instructions (see
Additional file 1: Table S1 for further purchasing in-
formation). Due to the low concentration of genetic
material associated to vesicles, 2 μL of undiluted miR-
NAs were used for retrotranscription at 42 °C for 60
min. A third spike-in miRNA (UniSp6) from the same
kit (Exiqon) was used as retrotranscription control.
After enzyme inhibition at 95 °C for 5 min, cDNA was
diluted 1:80 and 4 μL were used for qPCR reaction
with ExiLENT SYBR Green Master Mix (Exiqon,
Vedbaek, Denmark) on a LightCycler 480 (Roche,
Basel, Switzerland), following kit’s instructions. For
each sample, miRNAs were analysed in duplicate and
the mean value was used in next data analyses. Amp-
lification of the used spike-ins (UniSp4, UniSp5, and
UniSp6) was performed in the same PCR pre-de-
signed panels (Exiqon, Vedbaek, Denmark) with an
interplate calibrator control miRNA (UniSp3).
Data analysis and statistical testing
All statistical analyses were performed using Prism 7
(GraphPad Software, Inc., CA, USA).
Regarding EV characterization, MFI values for EV-
markers, EV-concentrations, and EV-size are given as
mean ± SD. Two-tailed unpaired T-test was applied
(p < 0.05 was considered as statistically significant).
For qPCR analysis, Cq (quantification cycle) values were
determined for each qPCR and the average of duplicates
was obtained. The variability between the different plates
was corrected by the Cq values for UniSp3 as interplate
calibrator. As stable genes, RNA-isolation control spike-in
UniSp4 and the retro-transcription control spike-in
UniSp6 were considered as reference genes. The average
of the two Cq values was used as reference value to calcu-
late miRNA expression. Relative expression in DLB and
AD was estimated compared to healthy controls and rep-
resented as fold expression changes obtained by 2-ΔΔCt.
Considering the low number of samples, multiple compar-
isons between the three groups (DLB, AD and controls)
were performed using the Kruskal-Wallis non-parametric
test and Dunn’s test was used for multiple corrections. A
p-value below 0.05 was considered statistically significant.
One-variable area under the ROC curve (AUC) was calcu-
lated considering the expression change in order to assess
the possible diagnostic potential of each differentially
expressed miRNA by the Wilson/Brown method (Graph-
Pad Prism v7; 95% C.I., AUC > 0.750 was assessed as mini-
mum value to be considered as a good-potential
biomarker).
We have submitted all relevant data of our experi-
ments to the EV-TRACK knowledgebase (EV-TRACK
ID: EV180020) [35].
microRNA target prediction
A list of possible affected target genes for the differentially
expressed miRNAs by qPCR was obtained by miRGate
[36] database. Filtering of the software output data was
performed following the instructions of the developers.
We first considered validated targets, named “confirmed
predictions” and showing the number of confirmed data-
bases of gene-miRNA biding supporting this prediction
group in the output data. For the remaining suggested tar-
gets, we took into account the column named “computa-
tional predictions”, defined by the number of
computational methods supporting this prediction group.
These referred to genes bioinformatically predicted to be
regulated by the given miRNA, although no validation has
been reported. Target with more than one computational
prediction were also considered [36].
The relationship between the miRGate validated targets
(those predicted with more than 1 confirmed predictions)
were analysed with String [37] and Panther Gene Ontol-
ogy [38] Databases, obtaining an integrated clustered net-
work based on biological processes, cellular components
and KEEG (Kyoto Encyclopaedia of genes and genomes)
Pathways. In both cases, default settings were used. In
Panther GO-analysis, Fisher’s exact test was applied and
Bonferroni correction for multiple testing was used.
Results
EV isolation and characterization
EVs were isolated from 2mL of platelet-depleted plasma by
SEC from three different cohorts (healthy controls, DLB
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Fig. 1 (See legend on next page.)
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and AD), obtaining 20 fractions of 0.5mL from each sam-
ple. EV-fractions were identified by the presence of tetra-
spanins CD9, CD81, and CD63. Alternatively, some
samples were also profiled for the presence of CD5L, re-
cently described as plasma-EV marker [39]. In all cases,
EV-enriched fractions –positive marked for the 4 EV
markers used- were eluted, preceding the bulk of soluble
protein (Fig. 1A i). Three fractions showing the highest
MFI values of each sample were pooled for further experi-
ments. No differences in MFI and expression of EV-
markers were found between the three groups (Fig. 1A ii).
Some samples were submitted to cryo-electron microscopy
analysis confirming the presence of vesicles with the ex-
pected size and morphology (Fig. 1b). NTA data did not
show any difference in particle concentration or particle
size (Fig. 1c) between DLB and control groups.
Discovery phase: miRNA profiles of DLB and control
plasma-EVs
As first approach (discovery phase), 7 samples of
DLB patients and 7 samples of age-matched controls
were included for library construction and NGS ana-
lysis. An average of 4,364,157 ± 647,775 raw reads
per sample was obtained for control samples
(Additional file 2: Table S2); for DLB, we obtained 4,
307,581 ± 2,076,192 reads per sample. Although 311
mature miRNAs were identified among all samples,
only those showing at least 5 reads (n = 238) were
further considered. More than 95% of these miRNAs
were already included in vesicular databases EVpedia
[40] and ExoCarta [41] as related to EV or exosomes
from human samples (Fig. 2a). The hsa-let-7 family
appeared as one of the most representative miRNA
groups among our data set (Fig. 2b). The whole list
of all identified miRNA has been submitted to the
EVpedia database and entitled as this manuscript.
Statistical analyses of the 238 miRNAs identified by
NGS showed no differences between DLB and controls
(Wilcoxon p-value > 0.05 for all).
Selection of dementia related miRNAs for further qPCR
analysis
Despite the lack of differences and statistical significance
between DLB and healthy control cohorts, we carried out
a bibliographic search for those miRNAs that yielded
more than 5000 reads in the NGS experiment. Their asso-
ciation to dementia, DLB, AD and PD was examined and
a group of 15 miRNAs (Table 2), mainly associated to de-
mentia and AD, was further analysed by qPCR in three in-
dependent cohorts of samples.
(See figure on previous page.)
Fig. 1 Isolation and characterization of plasma-EVs. a EVs are eluted in low protein SEC fractions and EV-markers could be detected by bead-
based flow cytometry. An example graph for one of the processed samples is shown (i); MFI values of the tetraspanins CD9, CD63 and CD81, and
marker CD5L in the SEC-pooled fractions are represented. Bars represent mean +/−SD of 15 independent experiments in the case of tetraspanins
and 5 in the case of CD5L (ii); (b) Cryo-EM images with characteristic shape and size of isolated vesicles; (c) above: representative NTA profiles for
one control-EV and one DLB-EV sample, below: concentration and modal distribution for 6 control and 6 DLB samples (mean ± SD)
Fig. 2 Profiling and characterization of NGS data. a Mature miRNAs identified were compared to the already described as human-EV content in
ExoCarta and EVpedia; b Hsa-let-7 family was the most representative miRNA family in our data set
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Table 2 Selected microRNAs for further qPCR validation analysis
miRNA Previously reported in the literature Ref NGS
Counts





Down-regulated in serum-EVs from AD patients compared
to controls
[20] 14,337 1.49 (0.91–2.06) 1.81 (0.67–2.96) 0.29 (0.03–0.56)
Up-regulated in serum-EVs from PD patients in comparison
to AD
Down-regulated in CSF from AD patients compared to
control individuals
[42]





Deregulated in AD blood (different results in NGS and qPCR) [44] 27,896 1.88 (0.96–2.79) 1.04 (0.54–1.53) 0.8 (0.09–1.5)
miR-26a is up-regulated in CSF from PD patients compared
to controls
[21]




Down-regulated in CSF from AD patients compared to
controls
[19]
Down-regulated in serum from AD patients compared to
healthy controls
[47]
Down-regulated in ALS blood compared to controls [48]
hsa-let-7i-
5p
Down-regulated in PD brains compared to controls [49] 15,170 1.43 (0.78–2.09) 1.23 (0.05–1.75) 0.41 (0.06–0.75)
Increased expression in AD patients’ hippocampus [50]
Up-regulated in CSF from AD compared to controls. [42]
Down-regulated in ALS compared to controls [48]
hsa-miR-
126-3p




37,418 2.23 (1.41–3.04) 1.88 (0.66–3.1) 0.89 (0.03–1.74)
Increased expression in the hippocampus of AD mouse




Up-regulated in serum-EXs from MS patients compared to
controls
[53] 10,058 2.05 (1.21–2.88) 1.84 (0.76–2.92) 0.19 (0.05–0.33)
Increased in plasma from vascular dementia patients
compared to healthy controls
[54]
Decreased expression in CSF-EXs from AD compared to
controls
[55]
Down-regulated in ALS compared to controls [48]
hsa-miR-
23a-3p
Up-regulated in brain tissue from AD patients [50] 6834 1.85 (1.24–2.45) 1.17 (0.65–1.68) 0.52 (0.06–0.97)
miR-23a is down-regulated in serum samples from AD
patients’ vs FTD and controls
[56]
Down-regulated in blood from MS patients compared to
controls
[57]
Down-regulated in CSF from AD patients compared to
control individuals
[42]
Reflect MS disease status in serum-EXs [53]
Increased expression in brain tissue from AD patients
compared to controls
[51]
Down-regulated in ALS blood compared to controls [48]
hsa-let-7f-
5p
Up-regulated in AD hippocampus compared to healthy
controls
[50] 191,299 1.29 (0.59–1.99) 1.28 (0.23–2.34) 1.05 (0.33–1.76)
Up-regulated in AD serum compared to healthy controls [58]
Down-regulated in blood from AD patients compared to
controls
[45]
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Table 2 Selected microRNAs for further qPCR validation analysis (Continued)
miRNA Previously reported in the literature Ref NGS
Counts
Mean Fold change (2-ΔΔCt)
(95% C.I.)
CTRL DLB AD




Down-regulated in the prefrontal cortex of AD patients [50] 5236 1.48 (0.05–3.01) 1.46 (0.12–2.79) 1.35 (0.19–2.52)
Down-regulated in CSF from PD patients compared to
controls
[20]




Up-regulated in serum-EXs from MS patients compared to
controls
[53]





Down-regulated expression in serum from PD patients
compared to controls
[61] 30,066 1.89 (0.42–3.35) 1.22 (0.54–1.89) 1.38 (− 0.29–3.06)
Differentially expressed in PD and Huntington patients’ brain [62]
Up-regulated in CSF from AD patients compared to control
individuals
[42]
Down-regulated in the serum samples of AD patients’ vs
MCI subjects
[63]
Differentially expressed in AD and MCI [64]
hsa-let-7b-
5p
Let-7b miRNA is up-regulated in AD patients’ brain [51] 107,394 1.98 (0.07–3.89) 0.81 (0.39–1.23) 2.097 (0.58–3.61)
Let-7b is down-regulated in the white matter of AD patients [65]
Increased amounts of let-7b in CSF from AD patients [66]
Differentially expressed in AD in comparison to controls [64]
hsa-miR-
151a-3p
Up-regulated in AD blood compared to controls [44] 5798 2.04 (− 0.13–4.22) 0.98 (0.34–1.63) 0.70 (− 0.09–1.5)
Up-regulated in blood from AD patients compared to
controls
[45]
Differentially expressed in AD in comparison to controls [64]
hsa-miR-24-
3p
miR-24 is up-regulated in serum and plasma of MSA
compared to PD patients
[67] 10,896 1.5 (0.68–2.33) 1.49 (0.28–2.69) 25.21 (3.11–47.31)
Dow-regulated in plasma-EXs from AD patients compared to
controls
[22]
miR-24 is deregulated in CSF from AD patients [68]
Decreased expression in AD-CSF compared to controls [42,
69]
miR-24 expression is decreased in CSF from PD patients
compared to controls
[16]





miR-143 is up-regulated in AD brain patients [51] 17,380 5.85 (− 2.88–14.6) 1.22 (− 0.11–2.56) 2.42 (− 1.28–6.11)
Down-regulated in CSF from ALS patients compared to
controls
[71]
Increased expression in serum-EXs of AD patients vs healthy
controls
[23]
Down-regulated in serum from AD patients [72]
Up-regulated in CSF from AD and dementia patients
compared to controls
[42]
Up-regulated in brain of PD mouse model [73]
Increased expression in serum ALS compared to controls [74]
hsa-miR- Under-represented in the cortex of AD patients [50, 8928 1.99 (0.52–3.46) 1.23 (0.43–2.04) 8.04 (2.02–14.06)
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Validation phase: qPCR analysis of selected microRNAs in
DLB, AD and control cohorts
Three groups of samples including 11 DLB patients, 11
age-matched controls and 10 AD patients were used in
the expression analysis by qPCR of the 15 selected miR-
NAs. Confirming our previous analyses by NGS, no dif-
ferences were found for any of these miRNAs between
DLB and healthy controls (Fig. 3).
In contrast, two miRNAs were differentially down-
regulated in AD patients compared to DLB and
aged-matched controls (Fig. 3) – specifically hsa-
miR-451a (p = 0.0003 and p = 0.0031, vs controls and
DLB respectively) and hsa-miR-21-5p (p = 0.0075 and
p = 0.0064). Moreover, four miRNAs were also sig-
nificantly down-regulated also in AD compared to
the control cohort (Fig. 3) - hsa-miR-23a-3p (p = 0.0016),
hsa-miR-126-3p (p = 0.004), hsa-let-7i-5p (p = 0.0154), and
hsa-miR-151a-3p (p = 0.0335)-. The remaining nine
miRNAs (out of 15) did not show any statistical
difference between the three groups, though three of
them showed a trend to be over-expressed in AD
compared to DLB and controls –hsa-miR-183-5p,
hsa-miR-24-3p and hsa-miR-423-5p (Fig. 3). A pre-
dictive diagnostic value -based on ROC curves- to
discriminate between AD and DLB patients rendered
high specificity and sensitivity (AUC over 0.9) for
the miRNAs hsa-miR-451a and hsa-miR-21-5p
(Fig. 4).
microRNA target prediction and affected pathways
The six significantly and differentially down-regulated
miRNAs in AD compared to controls and/or DLB were
screened for their possible target genes using miRGate
software. Up to 217 genes were predicted to be poten-
tially regulated by these miRNAs and already validated
as targets by 2 or more tools. These genes were further
analysed and networked using String and Panther data-
bases. Most of the analysed genes were related to meta-
bolic processes (p = 1.6•10E-9), specifically protein
metabolic processes (p = 5.1•10E-7). Among them, 37
were involved in the regulation of phosphorylation
processes (p = 1.8•10E-6); specifically related to MAPK
cascades and regulation of protein kinase activity (p =
0.009 and p = 1.2•10E-6, respectively). GO analysis for
biological process also revealed the enrichment of re-
sponse to stress (p = 4.3•10E-4), aging-related genes
(p = 0.01), genes involved in neuronal morphogenesis
and differentiation (p = 0.017 and p = 0.04, respectively).
Particularly, several genes were related to negative
regulation of neurogenesis and cell death (p = 0.003 and
p = 0.01, respectively). Focusing in the analysis of the 2
miRNAs differentially expressed in AD vs DLB and/or
controls, hsa-miR-451a and hsa-miR-21-5p, we found
an enrichment of genes related to SMAD protein phos-
phorylation (p = 3.8•10E-5).
Additionally, we screened the whole list of predicted
target looking for genes related to “neurodegeneration”
Table 2 Selected microRNAs for further qPCR validation analysis (Continued)
miRNA Previously reported in the literature Ref NGS
Counts




Increased expression in CSF from AD and dementia patients
vs controls
[42]
Down-regulated expression in PD putamen tissue [73]
Differentially expressed in AD blood compared to healthy
controls
[64]
Down-regulated in plasma from PD patients compared to
normal controls
[43]
Up-regulated in CSF from AD patients compared to controls [51]
Low expression in CSF from PD patients [75]
hsa-miR-
183-5p
In serum, associated to neurofibrillary tangles score in AD
patients
[20] 3820 1.18 (0.63–1.73) 0.79 (0.15–1.44) 15.77 (0.84–30.7)
Differentially expressed in AD and other types of dementia
patients vs controls
[42]
Down-regulated in peripheral blood from ALS patients [48]
Decreased expression is associated to PD [76]
Literature search was performed in different databases for the top most abundant miRNAs found by the exploratory Next Generation Sequencing (NGS) study.
PubMed, and the Nervous System Disease NcRNAome Atlas (NSDNA) (30) were used to explore their relation with neurodegeneation-related processes. Total read
count for each miRNA by NGS is shown; For qPCR analysis, mean and 95% C.I. is shown
Key: EVs Extracellular vesicles, AD Alzheimer’s disease, DLB Dementia with Lewy bodies, CSF Cerebrospinal fluid, PD Parkinson’s disease, MS Multiple Sclerosis, ALS
Amyotrophic lateral sclerosis, EXs Exosomes, FTD Frontotemporal dementia, MCI Mild cognitive impairment
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Fig. 3 MiRNA expression levels in DLB, AD and controls. MiRNAs with highest expression differences are shown first. From the 15 analysed
miRNAs, a 6-miRNA group showed significantly down-regulated expression in AD samples when compared to the two other cohorts. In all cases,
mean and range for fold change are plotted; (*p < 0.05, **p < 0.005, ***p < 0.0005)
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and potentially regulated by these six miRNAs. The
identified genes are listed in Table 3 and include
ADAM10 (ADAM Metallopeptidase Domain 10), APP
(β-amyloid precursor) and APPBP2 (amyloid protein-
binding protein 2).
Discussion
DLB and AD show an important neuropathological, neuro-
chemical and neuropsychiatric overlap, hampering correct
DLB diagnosis, treatment and clinical management. Gen-
etic and molecular characterization of these heterogeneous
and complex disorders will lead to a better handling and
diagnosis, although the definition of specific, differential
and early biomarkers is still required. Plasma-EVs may be-
come a promising reservoir of biomarkers also for neurode-
generative disorders. Besides their specific cell-derived
content and the RNase-protected environment [15], EVs
have been proved to cross the blood-brain barrier [10].
Therefore, although CSF would be the ideal source for spe-
cific biomarkers of central nervous system disorders, the
difficulty, invasiveness, morbidity, and risk related to CSF-
collection have paved the way for the analysis of plasma-de-
rived EVs also in these pathologic scenarios.
In the current study, we analysed for the first time the
miRNA content associated to plasma-EVs from DLB
and AD patients compared to healthy controls. No dif-
ferences in EV-markers, EV size, and morphology, or
particle concentration were observed between the differ-
ent cohorts. Our sequencing analysis focused on 238
miRNAs, most of them previously related to vesicles
from human samples [40, 41]. Accordingly, the let-7
family accounted for around 54% of the identified miR-
NAs, as previously reported [77]. Overall, the NGS ana-
lyses of miRNAs did not reveal significant differences
between DLB and aged-control samples.
Despite this lack of NGS significant results, a set
of 15 miRNAs previously described in the literature
as associated to neurodegenerative diseases and de-
mentia were analysed by qPCR in an independent
group of DLB and an additional group of AD pa-
tients compared to a different control cohort of
neurologically unaffected individuals. Of notice, 10
of these miRNAs have been described among the
most abundant miRNAs in the human brain [78].
No difference was observed in the expression of any
of the analysed miRNAs between DLB and controls,
as predicted by NGS results. However, 6 miRNAs
(hsa-miR-451a, hsa-miR-21-5p, hsa-miR-23a-3p, hsa-
miR-126-3p, hsa-let-7i-5p, and has-miR-151a-3p)
were significantly down-regulated in AD patients
compared to DLB or controls. Noteworthy, all these
six miRNAs are also described as extracellular space-
or exosome- associated in NCBI/Gene database. Our
results are in line with previous observations on the
reduced expression of hsa-miR-23a-3p in AD serum
compared to controls [56] and the down-regulation
of hsa-miR-126 previously described in CSF derived
vesicles from AD patients [21, 51]. Besides confirm-
ing these previous studies, our expression results
further indicate that DLB and AD patients may be
distinguished by determining some of these miRNAs,
as specifically shown by the expression profile of
miRNAs hsa-miR-451a and hsa-miR-21-5p.
In comparison to healthy controls, hsa-miR-451a was
previously described as down-regulated in CSF-derived
AD-exosomes [55], and hsa-miR-21-5p was down-regu-
lated in serum and CSF from AD patients [20, 42]. There-
fore, both miRNAs were reported as putative biomarkers
for AD. Here we confirmed the down-regulation of these
two miRNAs also in plasma-derived EVs of AD patients
compared to controls and, additionally to DLB. Finally, in-
creased levels of hsa-let-7i-5p have been described in brain
and CSF of AD patients [42, 50]. Also, up-regulation of
hsa-miR-151a-3p has been reported in blood from AD pa-
tients in comparison to controls [44, 45]. These results are
contradictory to our expression data that showed a reduced
expression in AD versus controls in both cases. Having no
reason to explain this later observation, it has been pro-
posed that plasma and/or plasma-EV concentration of a
given molecule including miRNA do not always show the
same tendency [79], and the expression levels in peripheral
circulation can also differ from those observed in CSF [42].
Fig. 4 ROC curves for the differentiation between DLB and AD. Highest AUC ROC curves were obtained for hsa-miR-21-5p and hsa-miR-451a
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As a preliminary approach to evaluate the discrimin-
ation power of these miRNAs, ROC curves for the AD
down-regulated miRNAs were calculated. Hsa-miR-21-5p
and hsa-miR-451a rendered high AUC values to be
considered a putative bio-signature for AD-DLB
discrimination. Nevertheless, given the small number of
samples analysed in this study, these results must be taken
as tentative and as a first proof-of-concept, needing fur-
ther validation in larger cohorts of patients. Likewise, it
would be neither accurate to establish a specific
Table 3 Neurodegenerative processes-related genes among the target output from the differentially expressed miRNAs
Input Gene Input miRNA Start Stop Computational Predictions Confirmed Predictions
ADAM10 hsa-let-7i-5p 783 801 Miranda 0
hsa-miR-23a-3p 1477 1499 Miranda 0
hsa-miR-451a 3640 3660 Miranda 0
AKT1 hsa-miR-451a 60 79 Miranda Mirtarbase
APP hsa-let-7i-5p 532 553 Miranda 0
APPBP2 hsa-let-7i-5p 3533 3553 Miranda 0
hsa-miR-151a-3p 1868 1888 Miranda 0
hsa-miR-21-5p 4099 4120 Miranda 0
BCL2 hsa-miR-126-3p 4169 4192 Miranda 0
hsa-miR-23a-3p 4400 4418 Miranda 0
CASP2 hsa-let-7i-5p 2265 2285 Miranda 0
hsa-miR-151a-3p 2025 2045 Miranda 0
CASP3 hsa-let-7i-5p 141 160 Miranda 0
hsa-miR-23a-3p 808 828 Miranda 0
CASP8 hsa-miR-21-5p 867 888 Miranda 0
hsa-let-7i-5p 118 139 Miranda 0
CASP10 hsa-miR-23a-3p 2104 2124 Miranda 0
CASP14 hsa-let-7i-5p 56 77 Miranda 0
CCNE2 hsa-miR-126-3p 1212 1233 Miranda Mirtarbase
hsa-miR-151a-3p 249 270 Miranda 0
hsa-let-7i-5p 350 370 Miranda 0
COX6B2 hsa-let-7i-5p 69 91 Miranda 0
COX6C hsa-miR-21-5p 312 332 Miranda 0
COX7A1 hsa-let-7i-5p 49 54 Rnahybrid 0
COX7B hsa-let-7i-5p 301 321 Miranda 0
hsa-miR-23a-3p 832 852 Miranda 0
COX11 hsa-miR-151a-3p 1584 1604 Miranda 0
GSK3B hsa-miR-21-5p 912 934 Miranda 0
hsa-let-7i-5p 320 342 Miranda 0
hsa-miR-21-5p 5125 5147 Miranda 0
hsa-miR-23a-3p 988 1008 Miranda 0
MIF hsa-miR-451a 90 109 Miranda Mirtarbase|OncomiRDB|
UBE2J1 hsa-miR-23a-3p 1920 1942 Miranda 0
UBE2G2 hsa-let-7i-5p 251 272 Miranda 0
UBE2L3 hsa-miR-451a 322 343 Miranda 0
hsa-miR-23a-3p 1188 1209 Miranda 0
MirGate results for Computational and (when possible) Confirmed target genes are shown (in alphabetical order). The name of the prediction tool reporting each
target gene is indicated. “0” means no confirmation was found in the analysis for that specific target. Start and Stop indicate the miRNA binding site (beginning
and ending nucleotide) in the targeted gene sequence. Key: ADAM10 ADAM Metallopeptidase Domain 10), APP, β-amyloid precursor), APPBP2 Amyloid protein-
binding protein 2, GSK3B Glycogen synthase kinase 3, AKT1 RAC-alpha serine/ threonine-protein kinase, CAB39 Calcium binding protein 39, CASP Caspase, CCNE
Cyclin E, COX Cytochrome c oxidase, MIF Macrophage migration inhibitory factor, UBE2 Ubiquitin Conjugating enzyme E2
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correlation between miRNA levels and the clinical charac-
teristics of the studied groups. Moreover, as plasma-EV
associated miRNAs have been analysed, diverse causes,
such as age, patient characteristics or the existence of con-
comitant pathologies in these aged patients, could also
alter and modify these miRNAs, which seem to be
deregulated.
It is known that different miRNAs can converge on
the same function or be involved in the same molecular
pathway. The deregulation and differential expression of
these miRNAs in AD and DLB could be not only a cause
or specific result of each disease, but a consequence of a
common neurodegenerative process. Nevertheless, a pre-
liminary target gene prediction for the 6 down-regulated
miRNAs in our study defined a group of 217 most con-
firmed target genes (with more than 2 confirmed predic-
tions), mostly implicated in metabolic processes and
protein phosphorylation. The role of protein-phosphor-
ylation during neurodegeneration has been widely de-
scribed as important in the spread and accumulation of
α-synuclein in DLB or PD brains [80, 81]. Also, the in-
creased levels of phosphorylated tau in AD have been
considered as an important marker of AD pathogenesis
[82]. Specifically, genes involved in the Pl3K-AKt path-
way, such as CAB39 [83], are among the predicted genes
in our analysis. Together with AKT1, CAB39 would be
possibly regulated by hsa-miR-451a. Therefore, our data
suggest an impairment of this pathway, involved in
neuron differentiation-proliferation and death [84].
Other genes related to neurodegeneration were also
found, although with a lower prediction rate (Table 3).
For instance, ADAM10, APPBP2 and APP, identified as
hsa-let-7i-5p targets, are directly involved in the intracel-
lular transport and deposition of β-amyloid peptides [85].
As inferred from our results, the reduction of hsa-miR-let-
7i-5p, together with hsa-miR-21-5p and hsa-miR-151a-3p,
could alter APPBP2 and APP expression resulting in an
incorrect APP cleavage and promoting β-amyloid accu-
mulation. Other genes like GSK3B (Glycogen synthase
kinase 3) may play a role in neuroinflammation [86], neur-
onal apoptosis and accumulation of phosphorylated tau -
in AD [87]. In our study, several miRNAs targeting
GSK3B were down-regulated in AD samples. Further-
more, cell-death related genes, such as BCL2, cyclins in-
volved in cell cycle or genes involved in the degradation of
selective proteins (including β-amyloid peptide) such as
proteasomal proteins were also present in the predicted
network. The impairment of the proteasomal pathway
would increase β-amyloid deposition and promote AD
pathology [88]. Of notice, among the miRNAs and pos-
sible target genes differentially regulated in DLB vs AD
(hsa-miR-21-5p and hsa-miR-451a) we found genes re-
lated to SMAD protein phosphorylation. The role of
SMAD proteins in AD has been described, by the
presence of smad2 within amyloid plaques and neurofib-
rillary tangles [89].
Altogether our data point to a specific reduced expres-
sion of AD-related miRNAs that would target genes pri-
marily involved in protein phosphorylation cascades and
the neuropathology of AD. The differential expression of
these miRNAs in AD versus DLB patients could be con-
sidered as a putative biomarker for the identification/dis-
crimination between both disorders, which could help
neurologist to overcome the clinical and pathological
overlap between AD and DLB. Nevertheless, as a first
exploratory study, these data have to be further con-
firmed in larger cohorts of patients.
Conclusions
To our knowledge, this is the first study on the compari-
son of the miRNA profile associated to plasma-EVs from
DLB and AD patients. Despite the limited number of
samples, our study provides preliminary evidence for dif-
ferent miRNA expression levels between the two most
common types of degenerative dementia, with changes
related to target genes and pathways involved in the
pathogenesis of AD.
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